Clinical Trial Update: International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

View source ↗

Summary

An international, multicenter extension study evaluated lixivaptan in patients with chronic hyponatremia and completed a 28-week open-label dosing period. The e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Lixivaptan (lixivaptan)

Snippet

Sponsor: CardioKine Inc. | Conditions: Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume | Status: COMPLETED